Physician profile
Michael Lawrence Grimaldi
NPI 1952831216
$3,966.74
in general payments reported to CMS, 2019-2025
18 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $1,611 · 2023: $1,097 · 2024: $807 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,665.62 | 2021-2025 | Intellis Adaptivestim, Vectris Surescan, Inceptiv |
| Nevro Corp. | $207.53 | 2023-2024 | Senza |
| Mml US, INC. | $151.09 | 2024 | Reactiv8 |
| Stryker Corporation | $147.57 | 2022-2025 | Optablate |
| Spr Therapeutics, INC | $123.00 | 2021-2025 | Sprint Pns System |
| Spinal Simplicity, LLC | $87.59 | 2022 | |
| Glaxosmithkline, LLC. | $83.70 | 2022-2023 | Benlysta |
| Collegium Pharmaceutical, INC. | $77.29 | 2022-2023 | Belbuca, Xtampza |
| Vertos Medical, INC. | $77.05 | 2023 | Mild Device Kit |
| Boston Scientific Corporation | $72.09 | 2023 | Infinion 16 |
| Abbvie INC. | $54.85 | 2023 | |
| Abbott Laboratories | $53.92 | 2023 | Proclaim |
| Scilex Pharmaceuticals INC. | $45.67 | 2022-2023 | Ztlido |
| Lenoss Medical INC | $36.40 | 2025 | Osteopearl |
| Globus Medical, INC. | $27.85 | 2025 | Senza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $22.62 | 2023 | Qutenza |
| Sanofi-Aventis U.S. LLC | $17.17 | 2023 | |
| Dynavax Technologies Corporation | $15.73 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grimaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.